Compare AAON & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AAON | MDGL |
|---|---|---|
| Founded | 1988 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9B | 12.8B |
| IPO Year | 1995 | 2005 |
| Metric | AAON | MDGL |
|---|---|---|
| Price | $82.33 | $504.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 19 |
| Target Price | $134.75 | ★ $682.11 |
| AVG Volume (30 Days) | ★ 1.1M | 188.1K |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | ★ 0.48% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.15 | N/A |
| Revenue | ★ $1,442,076,000.00 | $180,133,000.00 |
| Revenue This Year | $59.43 | $59.37 |
| Revenue Next Year | $17.53 | $39.35 |
| P/E Ratio | $74.00 | ★ N/A |
| Revenue Growth | ★ 20.11 | N/A |
| 52 Week Low | $73.19 | $393.61 |
| 52 Week High | $150.46 | $615.00 |
| Indicator | AAON | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 50.47 | 41.13 |
| Support Level | $75.02 | $501.44 |
| Resistance Level | $88.17 | $543.75 |
| Average True Range (ATR) | 3.49 | 15.08 |
| MACD | 1.19 | -2.69 |
| Stochastic Oscillator | 46.99 | 18.82 |
AAON Inc is a manufacturer of air-conditioning and heating equipment. The products include rooftop units, chillers, packaged outdoor mechanical rooms, air-handling units, makeup air units, energy-recovery units, condensing units, geothermal heat pumps, and self-contained units and coils. The company operates through three segments: AAON Oklahoma, AAON Coil Products, and BASX. It generates the majority of its revenue from the AAON Oklahoma segment which derives maximum revenue, engineers, manufactures, and sells, semi-custom, and custom HVAC systems, designs and manufactures control solutions, and sells retail parts to customers through retail part stores and online.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.